Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29 [Yahoo! Finance]
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Yahoo! Finance
Therapeutics, Inc. (NASDAQ:NRIX) to $28 from $29 on April 9, maintaining an Overweight rating on the shares and stating that although management is continuing execution on bexdeg's chronic lymphocytic leukemia trials with some modest updates expected at EHA, Wells believes bexdeg's opportunity in immunology and inflammation remains underappreciated. The firm also stated that it sees data from ONC's BTKdeg BGB-16673 for chronic spontaneous urticaria in the first half of 2026 as a potential upside catalyst. Nurix Therapeutics, Inc. (NASDAQ:NRIX) also received a rating update from Stifel on April 8, with the firm bringing the price target on the stock down to $34 from $35 while maintaining a Buy rating on the shares. The rating update came after the company reported a GAAP net loss wider than the firm's and consensus estimates, which was driven primarily by the recognition of lower-than-expected collaborative revenue. Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biophar
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics (NRIX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide [Seeking Alpha]Seeking Alpha
- Nurix Therapeutics (NRIX) had its price target lowered by Wells Fargo & Company from $29.00 to $28.00. They now have an "overweight" rating on the stock.MarketBeat
- Nurix Therapeutics (NRIX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire
NRIX
Earnings
- 1/28/26 - Beat
NRIX
Sec Filings
- 4/8/26 - Form 10-Q
- 4/8/26 - Form 8-K
- 4/2/26 - Form 4
- NRIX's page on the SEC website